Key result
Support vector classification models predicted hERG channel inhibition with an average AUC-ROC of 0.93 for 4,323 tested compounds and 0.86 in an external validation set of 66 drug molecules.
Effect estimate: AUC-ROC 0.93
Support vector classification models demonstrate high predictive accuracy for hERG channel inhibition, providing a useful computational tool for early-stage drug discovery.
May aid early hERG liability screening in drug design; leaves open prospective validation before clinical translation.
) channels. The hERG channel is one of the most important antitargets to be addressed in the early stage of drug discovery process, in order to avoid more costly failures in the development phase. Using a thallium flux assay, 4,323 molecules were screened for hERG channel inhibition in a quantitative high throughput screening (qHTS) format. Here, we present support vector classification (SVC) models of hERG channel inhibition with the averaged area under the receiver operator characteristics curve (AUC-ROC) of 0.93 for the tested compounds. Both Jackknifing and bootstrapping have been employed to rebalance the heavily biased training datasets, and the impact of these two under-sampling rebalance methods on the performance of the predictive models is discussed. Our results indicated that the rebalancing techniques did not enhance the predictive power of the resulting models; instead, adoption of optimal cutoffs could restore the desirable balance of sensitivity and specificity of the binary classifiers. In an external validation set of 66 drug molecules, the SVC model exhibited an AUC-ROC of 0.86, further demonstrating the utility of this modeling approach to predict hERG liabilities.
No takes yet. Share an insight, caveat, or question.
Sun et al. (2016) studied hERG channel inhibition (n=4,323). Support vector classification (SVC) models was evaluated on AUC-ROC for hERG channel inhibition (AUC-ROC 0.93). Support vector classification models predicted hERG channel inhibition with an average AUC-ROC of 0.93 for 4,323 tested compounds and 0.86 in an external validation set of 66 drug molecules.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: